title: Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4.
abstract: A novel paradigm in tumor biology suggests that cancer growth is driven by stem-like cells within a tumor. Here, we describe the identification and characterization of such cells from colon carcinomas using the stem cell marker CD133 that accounts around 2% of the cells in human colon cancer. The CD133(+) cells grow in vitro as undifferentiated tumor spheroids, and they are both necessary and sufficient to initiate tumor growth in immunodeficient mice. Xenografts resemble the original human tumor maintaining the rare subpopulation of tumorigenic CD133(+) cells. Further analysis revealed that the CD133(+) cells produce and utilize IL-4 to protect themselves from apoptosis. Consistently, treatment with IL-4Ralpha antagonist or anti-IL-4 neutralizing antibody strongly enhances the antitumor efficacy of standard chemotherapeutic drugs through selective sensitization of CD133(+) cells. Our data suggest that colon tumor growth is dictated by stem-like cells that are treatment resistant due to the autocrine production of IL-4.
authors: Department of Surgical and Oncological Sciences, Cellular and Molecular Pathophysiology Laboratory, University of Palermo, 90127 Palermo, Italy.
authors: Matilde
authors: M
authors: Todaro
authors: Mileidys Perez
authors: MP
authors: Alea
authors: Anna B
authors: AB
authors: Di Stefano
authors: Patrizia
authors: P
authors: Cammareri
authors: Louis
authors: L
authors: Vermeulen
authors: Flora
authors: F
authors: Iovino
authors: Claudio
authors: C
authors: Tripodo
authors: Antonio
authors: A
authors: Russo
authors: Gaspare
authors: G
authors: Gulotta
authors: Jan Paul
authors: JP
authors: Medema
authors: Giorgio
authors: G
authors: Stassi
mesh_terms: D000071916:AC133 Antigen; D000368:Aged; D000818:Animals; D015703:Antigens, CD / Q000378:metabolism; D000970:Antineoplastic Agents / Q000494:pharmacology; D016923:Cell Death / Q000187:drug effects; D045744:Cell Line, Tumor; D003110:Colonic Neoplasms / Q000473:pathology*; D005260:Female; D005472:Fluorouracil / Q000494:pharmacology; D006023:Glycoproteins / Q000378:metabolism; D006801:Humans; D015847:Interleukin-4 / Q000096:biosynthesis*; D008297:Male; D051379:Mice; D008819:Mice, Nude; D008875:Middle Aged; D014411:Neoplastic Stem Cells / Q000187:drug effects / Q000473:pathology*; D009500:Neutralization Tests; D009944:Organoplatinum Compounds / Q000494:pharmacology; D000077150:Oxaliplatin; D010455:Peptides / Q000378:metabolism; D019948:Receptors, Interleukin-4 / Q000378:metabolism; D018874:Spheroids, Cellular / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D023041:Xenograft Model Antitumor Assays
chemical_list: D000071916:AC133 Antigen; D015703:Antigens, CD; D000970:Antineoplastic Agents; D006023:Glycoproteins; D009944:Organoplatinum Compounds; C000606023:PROM1 protein, human; D010455:Peptides; C000606024:Prom1 protein, mouse; D019948:Receptors, Interleukin-4; D000077150:Oxaliplatin; D015847:Interleukin-4; D005472:Fluorouracil